“We’re not doing 30 bets a year”: Vijay Pande on betting small after running $4 billion at a16z
Source: TechCrunch ↗
Vijay Pande, the former head of Andreessen Horowitz’s roughly $4 billion biotech practice, left the firm in June of last year to launch VZVC, an AI‑native venture fund that will make only a handful of concentrated bets each year instead of the dozens he once oversaw. Co‑founded with longtime investor Zach Werner, VZVC operates without associates and leans heavily on artificial‑intelligence tools for its daily workflow, a stark contrast to the massive, associate‑driven operation Pande built after being recruited from Stanford, where he was best known for creating the Folding@home distributed‑computing platform. In a recent interview, Pande explained that his shift reflects a belief that biology is moving from a “science of discovery” to an engineering discipline, where AI can help identify drug targets, design molecules, and even streamline clinical trials—though the latter remain prohibitively expensive, often costing hundreds of millions of dollars and succeeding only about 20 % of the time.
The most consequential insight Pande offered is that the high failure rate of drug candidates stems not from flawed biology but from reliance on animal models that poorly predict human outcomes; AI‑driven synthetic data and predictive modeling could dramatically improve this odds ratio. By replacing murine experiments with more accurate computational simulations, developers could cut the cost and time to reach human trials, yet the expense of those trials still dominates drug pricing. Pande also highlighted that precision medicine is poised to benefit from this shift: while early efforts focused on genomics as a static blueprint, newer layers of data—proteomics, metabolomics, and high‑throughput robotic measurements—provide a dynamic view of an individual’s current physiological state. Coupled with AI, these data streams enable the design of therapies tailored to the patient rather than the population average, moving clinicians away from trial‑and‑error prescribing toward a model where the first drug administered is far more likely to be effective.
Looking ahead, Pande sees the convergence of AI for biology and AI for chemistry as the engine driving the next wave of therapeutic breakthroughs. The automation of laboratory measurements, the maturation of machine‑learning models that can predict protein‑drug interactions, and the growing availability of shared, open datasets—rather than proprietary, walled‑off collections—are all critical to unlocking AI’s full potential in medicine. He warns that most biotech firms currently hoard data, limiting broader progress, and argues that an ecosystem of open data will democratize insights and accelerate innovation across the industry. As VZVC pursues its limited, high‑impact investments, the firm aims to demonstrate that a focused, AI‑first approach can yield outsized returns while also paving the way for more affordable, precisely targeted treatments that could reshape the economics of drug development and patient care.
⚡ Effects Interpreter
🌍World Economylow impact
What this means for you
- ▶World markets have a habit of reading between the lines of stories like this.
- ▶Trade and investment between countries may shift a touch if things escalate.
🏙️Local Economylow impact
What this means for you
- ▶The knock-on for local trade is usually gradual rather than sudden.
- ▶Your town's economy tends to catch up with big headlines eventually.
🏦Rates & Banksmedium impact
What this means for you
- ▶Base rate decisions are usually made on data trends, not single headlines.
- ▶A sudden leap in mortgage costs from this alone would be out of character for lenders.
❤️Healthmedium impact
What this means for you
- ▶Staying calm and informed tends to help more than worrying alone.
- ▶Small, sensible precautions can go a long way here.
💷Wealthmedium impact
What this means for you
- ▶The financial side of health news is easy to overlook, but it adds up.
- ▶Days lost to illness can quietly dent household income.
🏠Housinglow impact
What this means for you
- ▶Buyers and renters might notice only a soft drift, if anything at all.
- ▶Renters might see costs drift a touch as landlords weigh their own bills.
🌍 Effects for your country
The U.S.'s central bank rate currently stands at 3.75%, so a global rates move like this could feed through to local borrowing costs. The U.S.'s economy is growing at 2.3% with inflation at 3.2%, the backdrop this story's effects play out against locally. Housing-market effects like this are usually felt most where mortgage rates track the U.S.'s own central bank rate closely. With the U.S.'s unemployment at 4.4%, personal-finance effects like this land on a labour market that is currently fairly stable. Health-system effects are harder to localise from economic indicators alone — the real impact in the U.S. depends more on local healthcare capacity than the figures above.
The UK's central bank rate currently stands at 3.75%, so a global rates move like this could feed through to local borrowing costs. The UK's economy is growing at 0.8% with inflation at 3.2%, the backdrop this story's effects play out against locally. Housing-market effects like this are usually felt most where mortgage rates track the UK's own central bank rate closely. With the UK's unemployment at 5.6%, personal-finance effects like this land on a labour market that is currently fairly stable. Health-system effects are harder to localise from economic indicators alone — the real impact in the UK depends more on local healthcare capacity than the figures above.
France's central bank rate currently stands at 2%, so a global rates move like this could feed through to local borrowing costs. France's economy is growing at 0.9% with inflation at 1.8%, the backdrop this story's effects play out against locally. Housing-market effects like this are usually felt most where mortgage rates track France's own central bank rate closely. With France's unemployment at 7.9%, personal-finance effects like this land on a labour market that is already under strain. Health-system effects are harder to localise from economic indicators alone — the real impact in France depends more on local healthcare capacity than the figures above.
Romania's central bank rate currently stands at 6.5%, so a global rates move like this could feed through to local borrowing costs. Romania's economy is growing at 0.7% with inflation at 7.8%, the backdrop this story's effects play out against locally. Housing-market effects like this are usually felt most where mortgage rates track Romania's own central bank rate closely. With Romania's unemployment at 6%, personal-finance effects like this land on a labour market that is currently fairly stable. Health-system effects are harder to localise from economic indicators alone — the real impact in Romania depends more on local healthcare capacity than the figures above.
The UAE's central bank rate currently stands at 3.65%, so a global rates move like this could feed through to local borrowing costs. The UAE's economy is growing at 3.1% with inflation at 2.5%, the backdrop this story's effects play out against locally. Housing-market effects like this are usually felt most where mortgage rates track the UAE's own central bank rate closely. Health-system effects are harder to localise from economic indicators alone — the real impact in the UAE depends more on local healthcare capacity than the figures above.